Hemab Therapeutics Holdings, Inc. Common Stock
COAG
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.57B
Close$
$45.13
16.4% downsideHemab Therapeutics Holdings Common Stock Target Price Details
Target Price by Analysts
16.4% downsideHemab Therapeutics Holdings Common Stock Target Price Details$3.1694.1% downside
Current Fair Value
94.1% downsideOvervalued by 94.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.57 Billion |
|---|---|
| Enterprise Value | $2.33 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.33 |
| Beta | 1.85 |
| Outstanding Shares | 30,111,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -41.94 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 3.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 20, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hemab Therapeutics Holdings, Inc. Common Stock
72 employees
CEO: Benny Sorensen Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience fo...